KPV: Reported Benefits, Side Effects and the State of the Evidence
Also referenced as: Lys-Pro-Val, α-MSH (11-13)
A literature-led overview of KPV — what has actually been measured in the published record, what remains unknown, and how research-grade material is characterised.
4 min read · Literature review · Updated 2026
Research-grade KPV vials — ≥99% HPLC purity, lot-matched COA on request, from $31.99.
Shop KPVWhat KPV is
The C-terminal tripeptide of α-MSH, investigated in inflammatory-pathway and mucosal research models.
Research material is supplied as a lyophilised powder in a sealed vial, reconstituted with bacteriostatic water immediately before use and characterised by reverse-phase HPLC with identity confirmed by mass spectrometry. The published record for KPV is dominated by preclinical sources, which is the most important caveat when reading any summary of its reported effects.
Reported benefits of KPV in the literature
The areas below summarise what published work has actually measured. Each is an observation reported in the cited literature — not a claimed outcome, and not a statement of efficacy in humans.
Inflammatory pathway research
Cell and rodent models have investigated NF-κB-associated signalling endpoints.
How it is described mechanistically
Mechanistic descriptions of KPV in the literature centre on the pathways below. Pathway attributions should be read as proposed rather than settled.
NF-κB pathway modulation
In-vitro literature describes reduced NF-κB nuclear translocation in stimulated cell models. Pathway noted in the literature: NF-κB signalling.
KPV side effects and safety data gaps
No controlled human safety data identified.
No consistent adverse-event profile has been established for KPV. The meaningful limitation is absence of data rather than a documented list of effects.
Open data gaps: human trials. Peptide Lounge does not publish dosing or administration guidance for any compound, and this material is not for human or veterinary use.
Purity, testing and handling for research use
Every KPV lot is released at ≥99% purity by RP-HPLC with identity confirmed by ESI-MS, and a lot-matched certificate of analysis is available on request rather than a generic sample document.
Vials ship lyophilised and sealed, and are stable at ambient temperature during transit. Store unreconstituted vials refrigerated and protected from light; once reconstituted, keep refrigerated and treat the solution as short-dated. Experimental concentrations must be determined by the researcher from the peer-reviewed literature under their own institutional protocol.
How researchers source KPV
KPV is stocked as a 10mg single-compound vial, with volume pricing applied automatically to multi-vial orders. Free bacteriostatic water and research supplies are included on qualifying orders.
Related research vials
KPV — frequently asked questions
What are the reported benefits of KPV?
Published work describes inflammatory pathway research. These findings come from preclinical or in-vitro studies rather than controlled human trials.
What side effects have been reported for KPV?
No established adverse-event profile exists. The substantive limitation is missing data: human trials.
Is KPV approved for human use?
No. KPV supplied by Peptide Lounge is a laboratory reagent for in-vitro and laboratory research only. It is not an approved drug and is not for human or veterinary use.
How is KPV stored and reconstituted?
Store lyophilised vials refrigerated and protected from light. Reconstitute with bacteriostatic water immediately before use and keep the resulting solution refrigerated. Vials remain stable at ambient temperature during shipping.
How do I verify the purity of a KPV vial?
Request the lot-matched certificate of analysis for the batch you received. It reports RP-HPLC purity (≥99%) and ESI-MS identity confirmation for that specific lot.
Research areas
Inflammatory pathway research
Preclinical dataCell and rodent models have investigated NF-κB-associated signalling endpoints.
Mechanisms of action (as described in literature)
NF-κB pathway modulation
In vitro dataIn-vitro literature describes reduced NF-κB nuclear translocation in stimulated cell models.
NF-κB signalling
Published studies
No peer-reviewed study links are curated for this compound yet. Available information is limited to analytical and preclinical sources. Absence of linked studies should be read as an evidence gap.
Safety signals & data gaps
Reported signals only — safety is not established
No controlled human safety data identified.
Known data gaps: Human trials.
For Research Use Only
All products listed are supplied strictly as laboratory reagents for in-vitro research and analytical work conducted by qualified professionals. They are not drugs, foods, cosmetics or medical devices, and must not be administered to humans or animals. No product on this site is approved by the FDA for human use.
Research Use Only: Products are sold strictly for laboratory research and educational purposes only. Not for human consumption, veterinary use, food use, cosmetic use, or therapeutic application. Products are not intended to diagnose, treat, cure, or prevent any disease.